Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 5 years, Star Imaging And Path Lab's highest 3-Year average EPS without NRI Growth Rate was 221.70% per year. The lowest was 36.30% per year. And the median was 129.00% per year.
Star Imaging And Path Lab (BOM:544482) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Star Imaging And Path Lab EPS (Diluted) Related Terms
Star Imaging And Path Lab EPS (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544482 vs TMO, DHR, IDXX: EPS (Diluted) Comparison
For the Diagnostics & Research subindustry, Star Imaging And Path Lab's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Imaging And Path Lab PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Star Imaging And Path Lab's PE Ratio distribution charts can be found below:
* The bar in red indicates where Star Imaging And Path Lab's PE Ratio falls into.
Star Imaging And Path Lab EPS (Diluted) Calculation
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Star Imaging And Path Lab's Diluted EPS for the fiscal year that ended in Mar. 2026 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹11.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Imaging And Path Lab (BOM:544482) has a EPS (Diluted) of ₹11.05 as of Mar. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Star Imaging And Path Lab and its competitors.
Is Star Imaging And Path Lab's EPS (Diluted) too high?
Star Imaging And Path Lab's current EPS (Diluted) is ₹11.05. Overall, Star Imaging And Path Lab has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Star Imaging And Path Lab's EPS (Diluted) compare to TMO and DHR?
Star Imaging And Path Lab's EPS (Diluted) of ₹11.05 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Medical Diagnostics & Research company?
A good EPS (Diluted) depends on the Medical Diagnostics & Research industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Star Imaging And Path Lab and its competitors. Star Imaging And Path Lab's current EPS (Diluted) is ₹11.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Imaging And Path Lab stock overvalued right now?
Star Imaging And Path Lab (BOM:544482) has a current EPS (Diluted) of ₹11.05. The current EPS (Diluted) is ₹11.05. Star Imaging And Path Lab's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Star Imaging And Path Lab (BOM:544482), the current EPS (Diluted) is ₹11.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Star Imaging And Path Lab Ltd operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi and Uttar Pradesh. It offers a comprehensive range of diagnostic imaging services and clinical laboratory tests, including both routine and specialized studies and profiles. These services are essential for the prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. The company's diagnostic imaging and radiology services encompass X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, ultrasounds, bone mineral densitometry, and mammography.
21GF Score
Get the complete analysis for BOM:544482
EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544482 has been successfully added to your 
